AR056404A1 - N-heteroarilpiperazinil ureas como moduladoras de la amida hidrolasa del acido graso y composicion farmaceutica - Google Patents
N-heteroarilpiperazinil ureas como moduladoras de la amida hidrolasa del acido graso y composicion farmaceuticaInfo
- Publication number
- AR056404A1 AR056404A1 ARP060102802A ARP060102802A AR056404A1 AR 056404 A1 AR056404 A1 AR 056404A1 AR P060102802 A ARP060102802 A AR P060102802A AR P060102802 A ARP060102802 A AR P060102802A AR 056404 A1 AR056404 A1 AR 056404A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- group
- unsubstituted
- disorders
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 235000014113 dietary fatty acids Nutrition 0.000 title 1
- 229930195729 fatty acid Natural products 0.000 title 1
- 239000000194 fatty acid Substances 0.000 title 1
- 150000004665 fatty acids Chemical class 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- -1 -C2-4alkenyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 2
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 abstract 2
- 229910052794 bromium Inorganic materials 0.000 abstract 2
- 229910052801 chlorine Inorganic materials 0.000 abstract 2
- 239000000460 chlorine Substances 0.000 abstract 2
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 208000016285 Movement disease Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003940 fatty acid amidase inhibitor Substances 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 230000002969 morbid Effects 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000002971 oxazolyl group Chemical group 0.000 abstract 1
- 230000036407 pain Effects 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000019116 sleep disease Diseases 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/01—Five-membered rings
- C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
- C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
- C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Abstract
Se describen ciertos compuestos de N-heteroarilpiperazinil urea, que son utiles como inhibidores de la FAAH. Dichos compuestos pueden ser usados en composiciones farmacéuticas y métodos para el tratamiento de estados morbosos, trastornos, y cuadros causados por la actividad de la amida hidrolasa del ácido graso (FAAH). En consecuencia, los compuestos pueden administrarse para tratar, p. ej., ansiedad, dolor, inflamacion, trastornos del sueno, trastornos de la alimentacion, o trastornos del movimiento (tales como esclerosis multiple). Reivindicacion 1: Un compuesto de formula (1), donde: Ar1 es un grupo piridilo, pirimidinilo, tiazolilo, oxazolilo, naftilo, o fenilo, no sustituido o sustituido en un miembro del anillo de carbono con una o dos porciones Ra; donde cada porcion Ra es seleccionada independientemente del grupo formado por -alquiloC1-4, -cicloalquiloC3-7, fenilo, benciloxi, -alqueniloC2-4, -NO2, -CN, -OH, -O-alquiloC1-4, fluor, cloro, bromo, yodo, -CF3, -OCF3, -SCF3, -SH, -S-alquiloC1-4, -SO2-alquiloC1-4, -SO-alquiloC1-4, -CO2-alquiloC1-4, -CO2H, -CO-alquiloC1-4, -SO2NRbRc, -NRbSO2Rc, -C(=O)NRbRc, -NRbC(=O)Rc, y -N(Rb)Rc, donde Rb y Rc se toman en conjunto para formar un anillo heterocicloalquilo de 4 a 7 miembros; y R2 es R3, R4, o Ar2, donde R3 es un grupo -N-piperidinilo, -N-piperazinilo, -N-morfolinilo, -N-tiomorfolinilo, -N-dioxo-1[lambda]6-tiomorfolinilo, o -N-pirrolidinilo, no sustituido o sustituido con una o dos porciones Rd; donde cada porcion Rd es seleccionada independientemente del grupo formado por -alquiloC1-4, -cicloalquiloC3-7, fenilo, -OH, y -alqueniloC2-4; R4 es -NReRf, donde Re y Rf son cada uno independientemente -H, -alquiloC1-4, o -cicloalquiloC3-7; y Ar2 es un grupo fenilo, tiofenilo, furanilo, piridilo, pirimidinilo, o pirazinilo, no sustituido o sustituido en un miembro del anillo de carbono con una o dos porciones Rg; donde cada porcion Rg es seleccionada independientemente del grupo formado por - alquiloC1-4, -cicloalquiloC3-7, fenilo, -alqueniloC2-4, -NO2, -CN, -O-alquiloC1-4, fluor, cloro, bromo, yodo, -CF3, -OCF3, -SCF3, -S-alquiloC1-4, -SO2-alquiloC1-4, -SO-alquiloC1-4, -CO2-alquiloC1-4, -CO-alquiloC1-4, -SO2NRhRj, -NRhSO2Ri, - C(=O)NRhRi, -NRbC(=O)Rc, y -N(Rh)Ri,. donde Rh y Ri son cada uno independientemente -H o -alquiloC1-4, o Rb y Rc se toman en conjunto para formar un anillo heterocicloalquilo de 4 a 7 miembros; y además donde Ar1 y R2 no son ambos fenilo no sustituido; o una sal farmacéuticamente aceptable, una prodroga farmacéuticamente aceptable, o un metabolito farmacéuticamente activo de dicho compuesto.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US69616605P | 2005-06-30 | 2005-06-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056404A1 true AR056404A1 (es) | 2007-10-10 |
Family
ID=37075785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP060102802A AR056404A1 (es) | 2005-06-30 | 2006-06-29 | N-heteroarilpiperazinil ureas como moduladoras de la amida hidrolasa del acido graso y composicion farmaceutica |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7541359B2 (es) |
| AR (1) | AR056404A1 (es) |
| PE (1) | PE20070099A1 (es) |
| TW (1) | TW200740801A (es) |
| WO (1) | WO2007005510A1 (es) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| US20070123572A1 (en) * | 2005-11-28 | 2007-05-31 | Kalypsys, Inc. | Novel method of preparation of 5-chloro-3-imidazol-1-yl-[1,2,4]thiadiazole and (3-imidazol-1-yl-[1,2,4]thiadiazol-5yl)-dialkyl-amines |
| SI2937341T1 (sl) | 2004-12-30 | 2017-10-30 | Janssen Pharmaceutica N.V. | Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj |
| GB0503056D0 (en) * | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| JPWO2008023720A1 (ja) * | 2006-08-23 | 2010-01-14 | アステラス製薬株式会社 | ウレア化合物又はその塩 |
| WO2008042892A2 (en) * | 2006-10-02 | 2008-04-10 | N.V. Organon | Fatty acid amide hydrolase inhibitors for energy metabolism disorders |
| ATE493984T1 (de) | 2006-10-18 | 2011-01-15 | Pfizer Prod Inc | Biaryl-ether-harnstoffverbindungen |
| KR20100017885A (ko) * | 2007-05-25 | 2010-02-16 | 얀센 파마슈티카 엔.브이. | 지방산 아미드 하이드롤라아제의 헤테로아릴-치환된 우레아 조절제 |
| WO2009105220A1 (en) * | 2008-02-19 | 2009-08-27 | Janssen Pharmaceutica N.V. | Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase |
| TWI434842B (zh) | 2008-07-14 | 2014-04-21 | Astellas Pharma Inc | Azole compounds |
| WO2010068453A1 (en) | 2008-11-25 | 2010-06-17 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| US8598356B2 (en) * | 2008-11-25 | 2013-12-03 | Janssen Pharmaceutica Nv | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase |
| CN102245604A (zh) | 2008-12-23 | 2011-11-16 | 雅培制药有限公司 | 抗病毒化合物 |
| CA2740193A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| AR075111A1 (es) * | 2008-12-24 | 2011-03-09 | Bial Portela & Ca Sa | Derivados heterociclicos de diazoles y triazoles, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de trastornos del metabolismo y del sistema nervioso, entre otros. |
| WO2010120935A1 (en) * | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| WO2010141809A1 (en) | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| PL2455376T3 (pl) | 2009-06-11 | 2015-06-30 | Abbvie Bahamas Ltd | Związki heterocykliczne jako inhibitory wirusa zapalenia wątroby typu C (HCV) |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| WO2011022348A1 (en) | 2009-08-18 | 2011-02-24 | Janssen Pharmaceutica Nv | Ethylene diamine modulators of fatty acid amide hydrolase |
| KR20120093425A (ko) * | 2009-12-11 | 2012-08-22 | 이 아이 듀폰 디 네모아 앤드 캄파니 | 지방산 아미드 가수분해효소의 아조사이클릭 억제제 |
| US20130029978A1 (en) | 2009-12-25 | 2013-01-31 | Mochida Pharmaceutical Co., Ltd. | Novel aryl urea derivative |
| BR112012016733A2 (pt) * | 2010-01-07 | 2015-09-01 | Du Pont | "composto, composição fungicida e método" |
| US20130150346A1 (en) | 2010-01-08 | 2013-06-13 | Quest Ventures Ltd. | Use of FAAH Inhibitors for Treating Parkinson's Disease and Restless Legs Syndrome |
| WO2011123719A2 (en) | 2010-03-31 | 2011-10-06 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating abdominal, visceral and pelvic pain |
| UA108233C2 (uk) | 2010-05-03 | 2015-04-10 | Модулятори активності гідролази амідів жирних кислот | |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| US9023852B2 (en) * | 2011-07-01 | 2015-05-05 | Remynd Nv | 1, 2, 4-thiadiazol-5-ylpiperazine derivatives useful in the treatment of neurodegenerative diseases |
| WO2013024168A1 (en) * | 2011-08-17 | 2013-02-21 | Remynd Nv | Piperazine thiazole derivatives useful in the treatment of tauopathies such as alzheimer's disease |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| HRP20211864T1 (hr) | 2015-07-06 | 2022-03-04 | Alkermes, Inc. | Inhibitori hetero-halo histonske deacetilaze |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| CA3002676A1 (en) | 2015-10-29 | 2017-05-04 | Dana-Farber Cancer Institute, Inc. | Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids |
| HRP20220223T1 (hr) | 2017-01-11 | 2022-04-29 | Alkermes, Inc. | Biciklički inhibitori histon deacetilaze |
| PL3664802T3 (pl) | 2017-08-07 | 2022-07-11 | Alkermes, Inc. | Bicykliczne inhibitory deacetylaz histonowych |
| GB201802326D0 (en) | 2018-02-13 | 2018-03-28 | Ucl Business Plc | Gene therapy |
| US12410137B2 (en) | 2023-07-17 | 2025-09-09 | Apogee Pharmaceuticals, Inc. | Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5347725Y2 (es) | 1971-06-18 | 1978-11-15 | ||
| US5612380A (en) | 1994-09-27 | 1997-03-18 | The Scripps Research Institute | Method for sleep induction |
| SK282252B6 (sk) | 1995-01-11 | 2001-12-03 | Samjin Pharmaceutical Co., Ltd. | Piperazínové deriváty a farmaceutický prostriedok s ich obsahom |
| US5856537A (en) | 1996-06-26 | 1999-01-05 | The Scripps Research Institute | Inhibitors of oleamide hydrolase |
| WO1998037077A1 (en) | 1997-02-24 | 1998-08-27 | Zymogenetics, Inc. | Calcitonin mimetics |
| JPH11139969A (ja) | 1997-08-07 | 1999-05-25 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| US6268367B1 (en) | 1998-02-23 | 2001-07-31 | Zymogenetics, Inc. | Piperazine derivatives for treating bone deficit conditions |
| US6462054B1 (en) | 2000-03-27 | 2002-10-08 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| JP2004525071A (ja) | 2000-07-20 | 2004-08-19 | ニューロジェン コーポレイション | カプサイシン受容体リガンド |
| US7662971B2 (en) | 2002-10-08 | 2010-02-16 | The Scripps Research Institute | Inhibitors of fatty acid amide hydrolase |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| FR2854633B1 (fr) | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| JP2007527397A (ja) * | 2003-07-01 | 2007-09-27 | マイクロバイア インコーポレイテッド | Ｃｏｘ−２及びｆａａｈ阻害剤 |
| FR2864080B1 (fr) | 2003-12-23 | 2006-02-03 | Sanofi Synthelabo | Derives de 1-piperazine-et-1-homopiperazine-carboxylates, leur preparation et leur application en therapeutique |
| FR2865205B1 (fr) | 2004-01-16 | 2006-02-24 | Sanofi Synthelabo | Derives de type aryloxyalkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| FR2866888B1 (fr) | 2004-02-26 | 2006-05-05 | Sanofi Synthelabo | Derives de alkylpiperazine- et alkylhomopiperazine- carboxylates, leur preparation et leur application en therapeutique |
| FR2866884B1 (fr) | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives d'aryl-et d'heteroaryl-piperidinecarboxylates, leur preparation et leur application en therapeutique |
| EP1830837B1 (en) * | 2004-09-20 | 2013-09-04 | Xenon Pharmaceuticals Inc. | Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes |
| TW200633990A (en) * | 2004-11-18 | 2006-10-01 | Takeda Pharmaceuticals Co | Amide compound |
| SI2937341T1 (sl) | 2004-12-30 | 2017-10-30 | Janssen Pharmaceutica N.V. | Fenilamidni derivati 4-(benzil)-piperazin-1-karboksilne kisline in z njimi povezane spojine kot modulatorji hidrolaze amidov maščobnih kislin (FAAH) za zdravljenje anksioznosti, bolečine in drugih stanj |
| GB0503056D0 (en) * | 2005-02-14 | 2005-03-23 | Smithkline Beecham Corp | Chemical compounds |
| KR101063663B1 (ko) | 2005-02-17 | 2011-09-07 | 아스텔라스세이야쿠 가부시키가이샤 | 피리딜 비방향족 질소 함유 헤테로환-1-카르복실산에스테르유도체 |
-
2006
- 2006-06-28 US US11/478,128 patent/US7541359B2/en active Active
- 2006-06-28 PE PE2006000759A patent/PE20070099A1/es not_active Application Discontinuation
- 2006-06-28 WO PCT/US2006/025343 patent/WO2007005510A1/en not_active Ceased
- 2006-06-29 TW TW095123448A patent/TW200740801A/zh unknown
- 2006-06-29 AR ARP060102802A patent/AR056404A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200740801A (en) | 2007-11-01 |
| PE20070099A1 (es) | 2007-02-06 |
| US7541359B2 (en) | 2009-06-02 |
| US20070004741A1 (en) | 2007-01-04 |
| WO2007005510A1 (en) | 2007-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR056404A1 (es) | N-heteroarilpiperazinil ureas como moduladoras de la amida hidrolasa del acido graso y composicion farmaceutica | |
| CR9277A (es) | Piperacinil y piperadinil ureas como moduladores de la amida hidrolasa de acido graso | |
| PE20070221A1 (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| ES2561163T3 (es) | Arilamidas del ácido bifenil-4-il-sulfónico y su uso como agentes terapéuticos | |
| AR038881A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un procedimiento para la preparcion de aquellos | |
| WO2017184624A1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| UY30649A1 (es) | Compuestos de biaril éter urea | |
| RU2013155586A (ru) | [1,3]оксазины | |
| EA201100698A1 (ru) | Производные тиенотриазолодиазепина, активные в отношении апо а1 | |
| RU95117070A (ru) | Производные циклоалкано-индола и -азаиндола, смесь их изомеров или отдельные изомеры и их соли, производные карбоновой кислоты в качестве исходных соединений для получения указанных производных и фармацевтическая композиция с антиатеросклеротической активностью | |
| HRP20100577T1 (hr) | Uporaba agomelatina za dobivanje lijeka s ciljem liječenja općeg poremećaja anksioznosti | |
| AR038883A1 (es) | Compuestos que modulan la actividad de ppar, composicion farmaceutica que los contiene y un metodo para prepararlos | |
| AR057034A1 (es) | Metodos para purificar tigeciclina | |
| ES3029609T3 (en) | Bicycloheteroaryl-heteroaryl-benzoic acid compounds as retinoic acid receptor beta (rarb) agonists | |
| RU2013108348A (ru) | Конденсированные гетероарилы и их применение | |
| CO6260069A2 (es) | Tiazolopiridin-2-iloxi-fenil y tiazolopirazin-2-iloxi-fenil aminas como moduladores de la leucotrieno a4 hidrolasa | |
| JP4793692B2 (ja) | 新規なｂｌｔ２介在性疾患、ｂｌｔ２結合剤および化合物 | |
| ES2675169T3 (es) | Procedimientos de tratamiento de las afecciones relacionadas con el cabello | |
| AR065377A1 (es) | Derivados de 4, 5, 6, 7-tetrahidro-pirazolo[3, 4-c]piridina, composiciones farmaceuticas que los comprenden y su uso para tratar enfermedades mediadas por la actividad de la catepsina s. | |
| MX2022015524A (es) | Formas cristalinas del acido {2-[3-ciclohexil-3-(trans-4-propoxi-c iclohexil)-ureido]-tiazol-5-ilsulfanil}-acetico y uso de las mismas. | |
| RU2009126653A (ru) | Средство для восстановления утраченной памяти в норме и патологии у пациентов всех возрастных групп на основе n,n'-замещенных 3,7-диазабицикло[3.3.1]нонанов, фармацевтическая композиция на его основе и способ ее применения | |
| RU2013142013A (ru) | Новые бензодиоксолпиперидины | |
| ES2527948T3 (es) | Uso de N-fenilamidas de ácido 2-sulfonilaminobenzoico sustituidas con sulfonilo en el tratamiento del dolor | |
| AR070291A1 (es) | AZAINDOL-3-CARBOXAMIDAS CíCLICAS, SU PREPARACIoN, SU USO COMO PRODUCTOS FARMACÉUTICOS Y SU EMPLEO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODULACIoN DE RAS. | |
| AR076516A1 (es) | Derivados de oxa-azaespiro[3.3]heptan-6-ilo, metodo e intermediarios para su preparacion, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por el receptor mch1. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |